---
document_datetime: 2023-09-21 22:03:11
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sonovue-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: sonovue-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.6578211
conversion_datetime: 2025-12-22 09:46:20.833872
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## SonoVue

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0051              | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                         | 20/12/2022                          | n/a                                         |                                  |           |
| II/0049              | Update of Annex II of the SmPC based on final results from study BR1-145 listed as a PAES in the Annex II; this is an observational, retrospective, multicentre, comparative study conducted in patients below 18 years of age who had undergone a VUS exam with intravesically administered | 10/11/2022                          |                                             | Annex II                         |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | SonoVue/Lumason or a VCUG exam as part of their standard of care for evaluation of known or suspected VUR. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0050   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/06/2022 | n/a |
| IA/0048/G | This was an application for a group of variations. B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters | 16/03/2022 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                         |            |            |                 |                                                                                                                                           |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2822/ 202009 | Periodic Safety Update EU Single assessment - sulfur hexafluoride                                                                                                                                                                                                                                                                                                                                                                                        | 24/06/2021 | 26/08/2021 | Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2822/202009. |
| IB/0046            | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                               | 25/08/2021 | n/a        |                 |                                                                                                                                           |
| IA/0045            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                            | 26/07/2021 | n/a        |                 |                                                                                                                                           |
| IB/0044            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                            | 26/05/2021 | 26/08/2021 | Annex II        |                                                                                                                                           |
| II/0039/G          | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are | 02/04/2020 | n/a        |                 |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                    | aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products   |            |            |             |                                                                                                                                                                            |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041            | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/03/2020 | 09/03/2021 | SmPC and PL |                                                                                                                                                                            |
| II/0040            | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                        | 12/03/2020 | 09/03/2021 | Annex II    |                                                                                                                                                                            |
| PSUSA/2822/ 201709 | Periodic Safety Update EU Single assessment - sulfur hexafluoride                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 17/05/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                          |
| II/0037/G          | This was an application for a group of variations. Grouped variation application in order to align with                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/04/2018 | 17/04/2019 | SmPC and PL | Use caution when treating anaphylaxis with epinephrine in patients on beta blockers since response may be poor or promote undesired alpha-adrenergic and vagotonic effects |

<div style=\"page-break-after: always\"></div>

| Company Core Data Sheet (CCDS): • Update of section 4.4 of the SmPC in order to reword the warning on hypersensitivity reactions. • Update of section 4.4 of the SmPC in order to reword the warning for patients with unstable cardiopulmonary status • Update of section 4.4 of the SmPC in order to delete the warning for patients on mechanical ventilation or with unstable neurological diseases • Update of section 4.4 of the SmPC in order to delete the warning for patients with clinically significant pulmonary disease, including severe chronic obstructive pulmonary disease • Update of section 4.8 of the SmPC in order to revise the table of Adverse Drug Reactions. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes/corrections in sections 4.8 and 4.9 of the SmPC. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | (hypertension, bradycardia). It should be emphasised that stress echocardiography not only can induce an ischaemic episode but also the stressors may induce predictable, dose-dependent effects on the cardiovascular system (e.g., increase in heart rate, blood pressure and ventricular ectopic activity for dobutamine, or decrease in blood pressure for adenosine and dipyridamole) as well as unpredictable, hypersensitivity reactions.   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                                  |                                                                       |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------|
| X/0034/G  | This was an application for a group of variations. Annex I_2.(e) Change or addition of a new route of administration C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                           | 22/06/2017 | 22/08/2017 | SmPC, Annex II, Labelling and PL | Please refer to the published assessment report for SonoVue X/0034/G. |
| IA/0036   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                  | 23/06/2017 | n/a        |                                  |                                                                       |
| IB/0035/G | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 15/03/2017 | n/a        |                                  |                                                                       |
| N/0031    | Update of the package leaflet in line with results of a user testing.                                                                                                                                                                                                                                                                                                                                                                         | 24/05/2016 | 22/08/2017 | PL                               |                                                                       |

<div style=\"page-break-after: always\"></div>

|                    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                            |            |            |                       |                                                                                                                                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0033/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place | 26/04/2016 | n/a        |                       |                                                                                                                                                   |
| IA/0032            | B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                                                                                        | 14/04/2016 | n/a        |                       |                                                                                                                                                   |
| PSUSA/2822/ 201409 | Periodic Safety Update EU Single assessment - sulfur hexafluoride                                                                                                                                                                                                                           | 23/04/2015 | 19/06/2015 | SmPC, Annex II and PL | Please refer to SonoVue - 000303 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation. |
| IAIN/0030          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                             | 30/04/2015 | n/a        |                       |                                                                                                                                                   |
| IA/0027            | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                  | 07/05/2014 | n/a        |                       |                                                                                                                                                   |
| II/0025            | These changes involve the deletion in Section 4.3 of the contraindications for use in patients with acute coronary syndrome or clinically unstable ischaemic                                                                                                                                | 25/04/2014 | 13/04/2015 | SmPC and PL           | Please refer to the CHMP AR for SonoVue II/0025.                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | cardiac disease and the insertion of these patient populations into Section 4.4 Special warnings and precautions for use, with editing of the wording as appropriate. These changes are also reflected in revised wording for the PIL. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data   |            |            |             |                                                                                                                                                                                                                                                                                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0026 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                          | 10/04/2014 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                |
| IA/0024   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                | 10/06/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                  |
| IB/0023   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                            | 08/01/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                  |
| II/0021   | Update of sections 4.4, 4.5 and 4.8 of the SmPC. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                 | 20/09/2012 | 24/10/2012 | SmPC and PL | The MAH proposed the update of sections 4.4 and 4.5 of the SmPC in order to add a warning about the concommitent use of beta blockers and the update of section 4.8 of the SmPC to add a table of adverse events of 'hypotension'. The Package Leaflet was proposed to be updated in accordance. |
| IA/0022/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding                                                                                                                                                                                      | 17/10/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | manufacturer for batch release) B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                           |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0020/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used                                                                                                                                                                      | 03/05/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0017   | Update of Summary of Product Characteristics and Package Leaflet. The MAH has applied to amend section 4.8 of the SPC in order to be in line with the Company Core Data Sheet (September 2009). The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update Annex II in line with the standard DDPS wording and to reflect the latest RMP version agreed with the CHMP. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 16/12/2010 | 24/01/2011 | SmPC, Annex II and PL | The integrated clinical trial database for SonoVue, from which the adverse events table in the new SPC is derived, contains 58 studies (8 healthy volunteer studies, 13 cardiac studies, 9 macrovasculature studies (i.e., Doppler sonography studies of arteries), 25 microvasculature studies (i.e., Doppler sonography studies of tissue microcirculation), and 3 special population studies). The database includes a total of 4653 subjects of whom 128 were healthy volunteers and 38 were special population patients. Safety data from myocardial perfusion studies (a total of 423 patients) were excluded from analysis since this indication is not approved in Europe. The MAH has applied to amend section 4.8 of the SPC in order to be in line with the Company Core Data Sheet (September 2009). |

<div style=\"page-break-after: always\"></div>

| IA/0019   | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/11/2010   | n/a        |             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| IB/0018/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing | 24/08/2010   | n/a        | takes place |
| IA/0016   | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 22/04/2009   | n/a        |             |
| II/0015   | The MAH applied for replacement of an analytical procedure. Update of or change(s) to the pharmaceutical documentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/11/2008   | 26/11/2008 |             |
| II/0014   | The MAH applied for additional manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/09/2008   | 02/10/2008 |             |

<div style=\"page-break-after: always\"></div>

|         | for manufacture, testing and secondary packaging. Update of or change(s) to the pharmaceutical documentation   |            |            |                                  |
|---------|----------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| N/0013  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)               | 29/01/2008 | n/a        | PL                               |
| IA/0012 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing               | 29/01/2008 | n/a        | Annex II and PL                  |
| IA/0010 | IA_47_c_Deletion of a pack size(s)                                                                             | 08/06/2006 | n/a        | SmPC, Labelling and PL           |
| R/0008  | Renewal of the marketing authorisation.                                                                        | 23/02/2006 | 24/04/2006 | SmPC, Annex II, Labelling and PL |
| II/0007 | Update of Summary of Product Characteristics and Package Leaflet                                               | 29/07/2004 | 27/09/2004 | SmPC and PL                      |
| N/0005  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)               | 03/03/2003 | 24/03/2003 | PL                               |
| II/0004 | Update of Summary of Product Characteristics and Package Leaflet                                               | 19/09/2002 | 04/12/2002 | SmPC and PL                      |
| N/0003  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)               | 18/03/2002 | 29/04/2002 | PL                               |
| N/0002  | Minor change in labelling or package leaflet not                                                               | 13/12/2001 | 19/02/2002 | PL                               |

<div style=\"page-break-after: always\"></div>

|         | with the SPC (Art. 61.3 Notification)                           |            |            | connected   |
|---------|-----------------------------------------------------------------|------------|------------|-------------|
| II/0001 | Change(s) to the manufacturing process for the active substance | 27/06/2001 | 04/07/2001 |             |